European-Latin American TB Research Collaboration Network

Informazioni relative al progetto

EUSAT-RCS

ID dell’accordo di sovvenzione: 823890

DOI

10.3030/823890

Progetto chiuso

Data della firma CE 26 Ottobre 2018

Data di avvio 1 Aprile 2019

Data di completamento 31 Marzo 2024

Finanziato da

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Costo totale

€ 910 800,00

Contributo UE

€ 910 800,00

Coordinato da

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Netherlands

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Documents, reports (6)

TB screening report

report on TB mass screening activities in vulnerable, highly endemic populations

TB epidemiology report

With the results from WP 4 and the mass screening report an in-depth analysis can be made from TB epidemiology in the penal institutions in Paraguay and measures may be discussed and prepared to decline the high TB incidence rates.

Systematic review and report

Systematic review and meta-analysis report of the in vivo and human experience of high dose rifampicin in DS-TB

Correlation report

Report on correlation of genetic polymorphisms, PK, treatment outcome in a mixed Paraguayan cohort and hard to treat patients from Europe and Latin America

Health care cost questionnaire

High dose rifampicin in vulnerable population report

Phase III Clinical trial protocol

we will review data regarding anti-TB drugs and make a reasoned decision about the best combination therapy to achieve a successful TB treatment outcome in a 4-month treatment duration. A study protocol, adapted to the circumstances present in Latin America and Europe, keeping all the international standards to ensure a high quality trial, will be designed. This design will especially prioritize low cost and simplicity compared to other aspects.

Other (2)

MGM workshop at INORMS conference

MGM staff from the consortium will provide a workshop on internationalising research at the INORMS conference 2020

external workshop pharmacogenetics

A workshop pharmacogenetic differences between Africans, Latin Americans and European TB patients will be given (at a conference)

Pubblicazioni

Peer reviewed articles (2)

Dried Blood Spot Sampling to Assess Rifampicin Exposure and Treatment Outcomes among Native and Non-Native Tuberculosis Patients in Paraguay: An Exploratory Study

Autori: Samiksha Ghimire; Gladys Molinas; Arturo Battaglia; Nilza Martinez; Luis Gómez Paciello; Sarita Aguirre; Jan-Willem C. Alffenaar; Marieke G. G. Sturkenboom; Cecile Magis-Escurra
Pubblicato in: Crossref, Numero 1, 2023, ISSN 1999-4923
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics15041089

Safety of Rifampicin at High Dose for Difficult-to-Treat Tuberculosis: Protocol for RIAlta Phase 2b/c Trial

Autori: Juan Espinosa-Pereiro; Samiksha Ghimire; Marieke G. G. Sturkenboom; Jan-Willem C. Alffenaar; Margarida Tavares; Sarita Aguirre; Arturo Battaglia; Gladys Molinas; Teresa Tórtola; Onno W. Akkerman; Adrian Sanchez-Montalva; Cecile Magis-Escurra
Pubblicato in: Crossref, Numero 1, 2022, ISSN 1999-4923
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics15010009